title: Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
authors.forename: R
authors.initials: R
authors.lastname: Itzykson
authors.forename: S
authors.initials: S
authors.lastname: Thépot
authors.forename: V
authors.initials: V
authors.lastname: Eclache
authors.forename: B
authors.initials: B
authors.lastname: Quesnel
authors.forename: F
authors.initials: F
authors.lastname: Dreyfus
authors.forename: O
authors.initials: O
authors.lastname: Beyne-Rauzy
authors.forename: P
authors.initials: P
authors.lastname: Turlure
authors.forename: N
authors.initials: N
authors.lastname: Vey
authors.forename: C
authors.initials: C
authors.lastname: Recher
authors.forename: S
authors.initials: S
authors.lastname: Boehrer
authors.forename: C
authors.initials: C
authors.lastname: Gardin
authors.forename: L
authors.initials: L
authors.lastname: Adès
authors.forename: P
authors.initials: P
authors.lastname: Fenaux
mesh_terms: D000963:Antimetabolites / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics*; D057176:Compassionate Use Trials; D005500:Follow-Up Studies; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D007621:Karyotyping; D009006:Monosomy; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D016016:Proportional Hazards Models; D016896:Treatment Outcome
chemical_list: D000963:Antimetabolites; D001374:Azacitidine